



Infectious Diseases Associated With Organized Sports and Outbreak Control

H. Dele Davies, MD, MS, MHCM, FAAP,^a Mary Anne Jackson, MD, FAAP,^b Stephen G. Rice, MD, PhD, MPH, FAAP,^c
COMMITTEE ON INFECTIOUS DISEASES, COUNCIL ON SPORTS MEDICINE AND FITNESS

Participation in organized sports has a variety of health benefits but also has the potential to expose the athlete to a variety of infectious diseases, some of which may produce outbreaks. Major risk factors for infection include skin-to-skin contact with athletes who have active skin infections, environmental exposures and physical trauma, and sharing of equipment and contact with contaminated fomites. Close contact that is intrinsic to team sports and psychosocial factors associated with adolescence are additional risks. Minimizing risk requires leadership by the organized sports community (including the athlete's primary care provider) and depends on outlining key hygiene behaviors, recognition, diagnosis, and treatment of common sports-related infections, and the implementation of preventive interventions.

abstract

FREE

^aPediatric Infectious Diseases and Public Health, University of Nebraska Medical Center, Omaha, Nebraska; ^bInfectious Diseases, Children's Mercy Kansas City and Department of Pediatrics, School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri; and ^cSports Medicine, Jersey Shore University Medical Center and Department of Pediatrics, Robert Wood Johnson Medical School, Rutgers University, Neptune, New Jersey

Dr Davies was the lead author of the manuscript; Drs Jackson and Rice were coauthors of the manuscript with substantial input into content and revision, and all authors approved the final manuscript as submitted.

This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication.

Clinical reports from the American Academy of Pediatrics benefit from expertise and resources of liaisons and internal (AAP) and external reviewers. However, clinical reports from the American Academy of Pediatrics may not reflect the views of the liaisons or the organizations or government agencies that they represent.

The guidance in this statement does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

All clinical reports from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

INTRODUCTION

The definition of organized sports includes traditional team sports commonly acknowledged as well as other types of sports (Table 1). Participation in organized sports provides the benefits of (1) physical activity, by engaging in vigorous exercise, achieving fitness, and learning athletic skills; (2) socialization, by experiencing camaraderie and learning teamwork and sportsmanship; and (3) competition, by challenging oneself to perform against others, by striving to continually improve oneself toward achieving one's full athletic potential, and by learning to win and lose with grace and dignity.¹ Organized sports participation, however, can result in the acquisition of a variety of infectious diseases and conditions. Physical contact among athletes, sharing of equipment (such as worn personal protective equipment or braces plus towels, drinking vessels, showers, and locker rooms), and contact with athletic surfaces (mats, artificial turf, dirt, grass, and gym or weight room equipment) can all be responsible for transmission of infection.²⁻⁹ In addition, certain organized sports carry specific additional risks; for example, wrestlers

To cite: Davies HD, Jackson MA, Rice SG, AAP COMMITTEE ON INFECTIOUS DISEASES, AAP COUNCIL ON SPORTS MEDICINE AND FITNESS. Infectious Diseases Associated With Organized Sports and Outbreak Control. *Pediatrics*. 2017;140(4):e20172477

TABLE 1 Examples of Organized Sports Involving North American Children

Traditional Team Sports	Other Organized Sports
Baseball, softball, basketball, football, soccer, wrestling, ice hockey, field hockey, lacrosse, volleyball, tennis, swimming and diving, track and field, cross country, gymnastics	Cheerleading, dance, martial arts, strength training, weightlifting, cycling, skiing, snowboarding, ultimate frisbee, boxing, figure skating, golf, skateboarding, distance running

practicing in close quarters are especially vulnerable to skin infections.^{10,11}

Athletes should be taught proper personal hygiene (eg, hand-washing, showering, and proper laundering of uniforms and practice clothing on a daily or regular basis),^{12–15} Avoidance of sharing of drinking vessels (water bottles, ladles, or cups), mouth guards, towels, braces, batting helmets, personal protective equipment, bars of soap, bath sponges, razors or electric hair shavers, and callus trimmers is also important in reducing infectious risk.^{2–9} In addition, athletic programs should ensure regular (daily, weekly, and monthly) cleaning of facilities and equipment (eg, weight room, railings, mats, blocking dummies, locker rooms, and showers).^{16–19} Those who manage sports programs and facilities should develop a plan for proper cleaning and maintenance of a sanitary sporting environment by using guidelines such as those published by the American College of Sports Medicine.²⁰

Special attention should be paid to proper management of blood and other body fluids.²¹ Just as hospitals in the United States have concentrated on preventing hospital-associated infections in recent years, the same level of focus on infection prevention and control needs to be present within the organized sports community, including among athletes, parents, coaches, athletic directors, equipment managers, certified athletic trainers, administrators, janitorial staff, team physicians, facility managers, and league officials.

Although the primary care pediatrician may appear to be peripheral in this athletic milieu of organized sports, leadership from physicians has always been welcome and expected regarding issues of public health and safety. Furthermore, because pediatricians need to provide medical clearance to athletes to participate in organized sports, the preparticipation physical examination is an opportunity to verify that the athlete does not have a skin condition or infection that could be transmitted to others. This visit between the physician and the student athlete allows the primary care pediatrician to deliver anticipatory guidance. Ensuring that immunizations are current per recommendations of the Centers for Disease Control and Prevention, the Advisory Committee on Immunization Practices, and the American Academy of Pediatrics is important, and pediatric providers should identify and document cases in which vaccines are refused or incomplete because of medical exemptions (eg, serious allergy to a vaccine component). Coaches and trainers are primarily responsible for reviewing and stressing to the athlete the key hygiene behaviors needed to minimize the risk of obtaining or spreading infection in organized sports. However, primary care pediatricians can help reinforce such educational messages.

ORGANISMS ASSOCIATED WITH INFECTIONS IN ATHLETES

An athlete can acquire many different infections by participating in organized sports. The pathogens

include many that are prominent in outbreaks typically seen in crowded communities or closed community settings or that are facilitated by certain exposures specific to the sport.

Infectious pathogens include those spread by skin contact (eg, *Staphylococcus aureus*, group A streptococcal skin infections, *Bacillus cereus*, herpes simplex virus [HSV], *Tinea capitis*, *Tinea corporis*, *Tinea pedis*, *Tinea cruris*, *Pediculosis capitis*, *Pediculosis corporis*, and *Pediculosis pubis*), by contaminated food or water (eg, Shiga-toxin producing *Escherichia coli*, *Shigella* species, *Giardia* species, *Cryptosporidium* species, and norovirus, which is further propagated by the person-to-person route), by respiratory droplet (eg, influenza, pertussis, *Neisseria meningitidis*, group A streptococcal pharyngitis, mumps), by airborne particles (eg, varicella, measles), or by certain vectors (eg, ticks) (Table 2). In the case of Epstein-Barr virus infection, close contact is required for transmission, and endemic disease within adolescent group settings has been reported (Table 2). Although biologically plausible, there have been no validated reports of infections from transmission of bloodborne pathogens, including hepatitis B, hepatitis C, or HIV during athletic competitions. Nonetheless, the American Academy of Pediatrics has previously issued specific detailed guidelines for management of infections spread by blood and body fluids, including guidance for athletes who are infected with HIV, hepatitis B virus, or hepatitis C virus, and these will not be reiterated in this statement.²¹

Transmission of a specific infectious agent may be affected by a variety of psychosocial (sexually transmitted infection), physical (trauma, closed community contact), and environmental (soil, food, water, vector) factors, especially in an

TABLE 2 Summary of Epidemiology and Outbreak Management Considerations for Organisms Responsible for Infections in Children Participating in Organized Sports

Pathogen or Disease	Transmission	Risk Factors	Rn, Dx, Tx	Prevention	Outbreaks and Other Considerations
<i>S aureus</i> including MRSA ²²	Contact	Contact sports, wounds (turf injuries in football or soccer), wrestling, rugby, judo, and gymnastic mats, sharing equipment	Rn: folliculitis, skin abscess, cellulitis, impetigo Dx: Gram-stain, culture of lesions Tx: cephalixin, TMP/SMX, or doxycycline based on susceptibility for 10 d	Good personal hygiene, wound care, avoid sharing equipment, refrain from use of common tubs, cosmetic shaving, cleaning of high-touch surfaces	Involve public health authorities for outbreaks Topical mupirocin depending on susceptibilities
GABHS ²³	Contact, droplet	Skin contact in impetigo/erysipelas, droplet in pharyngitis	Rn: impetigo, erysipelas, pharyngitis, cellulitis Dx: rapid antigen detection test for GABHS if sore throat and no viral symptoms, Gram-stain, culture of lesions Rx: treat if positive; culture skin lesions with amoxicillin or penicillin; if penicillin allergic, macrolide; all for 10 d except azithromycin for 5 d	Good hygiene, not sharing water bottles, equipment	Topical mupirocin if limited skin lesions Azithromycin for serious penicillin allergy
<i>B cereus</i> ²⁴	Contact, contaminated food	Sharing sunscreen, penetrating trauma, contaminated environment	Rn: honey-crusted skin lesions; rarely, necrotizing fasciitis; if contaminated food, nausea, vomiting, diarrhea, and cramps Dx: Gram-stain, culture of lesions, identification of enterotoxin from food if contaminated food Rx: usually IV vancomycin or linezolid for severe skin infections, supportive for foodborne	Good personal hygiene, avoid sharing equipment, sunscreen	Involve public health authorities for outbreaks ^{24,25}
HSV ²⁶	Contact with infected individual; reactivation 1° infection	Skin contact, wrestling, abraded skin, sun induced (eg, skiing)	Rn: cropped vesicles Dx: viral PCR of skin lesion Rx: adolescents-valacyclovir for 7 d	Valacyclovir prophylaxis, proper cleaning equipment	Identification and isolation of infected people Valacyclovir
Molluscum contagiosum ²⁷	Contact	Sharing towels, underlying eczema	Rn: pearly papule with central umbilication DX: clinical Rx: 10% KOH, cryotherapy	Avoid skin contact with infected people; no specific treatment is uniformly efficacious	Outbreaks have been reported
<i>T capitis</i> (<i>T tonsurans</i>), ²⁸ <i>T corporis</i> ²⁹	Contact	Skin contact, wrestlers, judo practitioners	Rn: scaly plaque, alopecia Dx: KOH prep, culture Rx: oral itraconazole, terbinafine, griseofulvin ± 1% terbinafine gel or 2% ketoconazole cream	In settings of high infection rates, in consultation with infectious diseases expert, consider fluconazole prophylaxis, 100 mg, once daily for 3 d, at season onset and repeat in 6 wk ³⁰	Griseofulvin contraindicated in pregnancy Topical for limited area <i>T corporis</i>

TABLE 2 Continued

Pathogens Primarily Transmitted by Contact Sports					
Pathogen or Disease	Transmission	Risk Factors	Rn, Dx, Tx	Prevention	Outbreaks and Other Considerations
<i>T pedis</i> ³¹	Contact	Common shower, skin contact, swimmers, skaters, marathon runners	Rn: scaly, itchy eruption on feet Dx: KOH prep, culture Rx: children 12 y or older – topical 0.77% ciclopirox cream or gel BID for 4 wk, 1% terbinafine gel OD for 1 wk, naftifine ointment BID for 4 wk. Oral terbinafine for 1 wk	Good personal hygiene Foot powder after bathing Careful drying between toes after showers Daily change of socks Periodic cleaning of footwear	—
<i>T cruris</i> ³²	Contact	Heat, humidity, hyperhidrosis, contaminated towels, hotel bedroom sheets	Rn: scaly, itchy eruption in groin area Dx: KOH prep, culture Rx: children 12 y or older, 1% terbinafine gel OD for 1 wk	Wear socks before undershorts if <i>T pedis</i> present Dry crural folds after bathing Use separate towel to dry groin and other parts of body	—
<i>Verruca vulgaris</i> (caused by subtypes of HPV) ³³	Contact	Wrestlers, sharing of equipment, bare feet in common shower areas	Rn: painless warts on hands and feet and under nails, firm hyperkeratotic papules Dx: clinical Rx: none or curettage, liquid nitrogen, laser removal or application of salicylic acid	Avoid contact with known infected people, no sharing of equipment and towels; wear rubber soled flip-flops or sandals in communal showers ³⁴	—
<i>S scabiei</i> (scabies) ³⁵	Contact	Wrestlers	Rn: ++ pruritic rash, interdigital webs Dx: Rx: topical permethrin 5% cream to whole body below neck (not pregnant women), remove by bathing after 8–14 h; oral ivermectin, 2 doses 1 wk apart for children >15 kg (not FDA-approved and not for pregnant girls), 10% crotamiton cream or lotion, or precipitated sulfur 4%–8%	—	Evaluate sparring partners; treat suspected cases Itching is attributable to hypersensitivity reaction and may not subside for weeks; not indication of treatment failure

TABLE 2 Continued

Pathogens Primarily Transmitted by Contact Sports					
Pathogen or Disease	Transmission	Risk Factors	Rn, Dx, Tx	Prevention	Outbreaks and Other Considerations
<i>Pediculus capitis</i> ³⁶ (head lice)	Contact	Sharing clothing, equipment	Rn: visible lice on hair shaft, pruritus Dx: clinical: seeing nits, nymphs, or adult lice with naked eye or hand lens Rx: manual removal of nits by fine-toothed combing. Start with over-the-counter topical 1% permethrin lotion or pyrethrin combined with piperonyl butoxide; repeat in 7 d; resistance reported, see text for options	Although risk of spread is low, sharing of combs, hair brushes, hats, and hair ornaments is not recommended ³⁷ No need to treat contacts prophylactically	Clearance by health care professional before resuming sport Rinse hair after topical pediculicide application over a sink rather than shower or bath to limit skin exposure, and use warm water instead of hot to limit absorption resulting from vasodilatation
Infectious mononucleosis caused by Epstein-Barr virus ³⁸	Close contact	Adolescent group settings	Rn: exudative pharyngitis, splenomegaly; serum antibody panel Dx: heterophile antibody test (>4 y of age), IgM antibodies versus viral capsid antigen, Epstein-Barr nuclear antigen Rx: supportive	Counsel regarding close contact and avoiding sharing drinks, utensils	Avoid contact sports until recovered and spleen no longer palpable (typically ~3–4 wk)
Pathogens primarily transmitted by airborne route Varicella ³⁹	Skin, airborne	Close community contact	Rn: crops of papules, vesicles, crusts; can be confused with HSV Dx: PCR of vesicular fluid Rx: usually none, oral acyclovir or valacyclovir for 7 d	Ensure ACIP/AAP-recommended varicella vaccine is given ³⁹	Ensure previous 2 doses of vaccine or history of disease for all exposed people Avoid salicylates during infection
Measles (rubeola) ⁴⁰	Droplet, airborne	International venues, underimmunized populations	Rn: febrile prodrome, morbilliform rash Dx: PCR of urine and nasopharyngeal specimens, rubeola serology Rx: supportive	Ensure ACIP/AAP-recommended MMR vaccine is given	Involve public health authorities for single case
Pathogens primarily transmitted by droplet route Mumps ⁴¹	Droplet	Crowded settings, underimmunized populations	Rn: parotitis Dx: PCR of saliva, serology Rx: supportive	Ensure ACIP/AAP-recommended MMR vaccine is given	Involve public health authorities for single case

TABLE 2 Continued

Pathogens Primarily Transmitted by Contact Sports				Outbreaks and Other Considerations	
Pathogen or Disease	Transmission	Risk Factors	Rn, Dx, Tx	Prevention	Outbreaks and Other Considerations
Influenza ⁴²	Droplet	Close community contact	Rn: febrile upper respiratory tract during influenza season Dx: culture, rapid molecular tests Rx: oseltamivir if identified in first 2 d, for 5 d	Ensure ACIP/AAP-recommended influenza vaccine is given seasonally	Prioritize treatment of those who have increased risk for influenza complications (eg, asthma, heart and/or lung disorders, metabolic disorders, immune compromised)
Pertussis ⁴³	Droplet	Close community contact	Rn: paroxysmal cough for ≥ 2 wk Dx: PCR of nasopharyngeal swab specimen Rx: azithromycin for 5 d	Ensure ACIP/AAP-recommended Tdap is given; identify and intervene with chemoprophylaxis in outbreaks	Involve public health authorities for outbreaks (>2 cases in closed population)
<i>N meningitidis</i> ⁴⁴	Droplet	Close community contact	Rn: bacteremic presentation, shock, purpura Dx: Gram-stain, culture Rx: begin with intravenous cefotaxime or ceftriaxone; penicillin once diagnosis confirmed	Ensure ACIP/AAP-recommended meningococcal conjugate ACWY vaccine is given	Involve public health authorities for single case; if serogroup B involved, meningococcal B vaccine
Pathogens primarily transmitted by contaminated food or water: route					
<i>Shigella</i> ⁴⁵	Contaminated food or water; person to person	Commonly attended event, restaurant related	Rn: diarrhea, blood Dx: culture stool Rx: TMP/SMX, ciprofloxacin depending on susceptibilities	Hand hygiene	Involve public health authorities for outbreaks
<i>Giardia</i> ⁴⁶	Contaminated food or water	Public pools, swimmers	Rn: watery diarrhea Dx: stool antigen test	Hand hygiene	—
<i>Cryptosporidium</i> ⁴⁷	Contaminated food or water	Public pools, swimmers	Rx: metronidazole or nitazoxanide Rn: watery diarrhea Dx: stool examination Rx: nitazoxanide	Hand hygiene	—
Norovirus ⁴⁸	Contaminated food or water; person to person	Common environment	Rn: abrupt onset of vomiting, watery diarrhea Dx: clinical RT-PCR Rx: supportive	Hand hygiene	Involve public health authorities for outbreaks
Leptospirosis ⁴⁹	Contaminated water	Triathletes, ⁵⁰ fresh water swimming, skin wounds	Rn: fever and headache, myalgia (can mimic influenza) Dx: enzyme-linked immunosorbent assay IgM Rx: intravenous penicillin G first choice, risk of Jarish-Herxheimer reaction; also cefotaxime, ceftriaxone and doxycycline; supportive care	Swimmers avoid immersion or swallowing potentially contaminated water Protective clothing, boots in contaminated water —	—

AAP, American Academy of Pediatrics; ACIP, Advisory Committee on Immunization Practices; BID, twice daily; Dx, diagnosis; FDA, Food and Drug Administration; HPV, human papillomavirus; IgM, immunoglobulin M; IV, intravenous; KOH, potassium hydroxide; OD, once daily; Rn, recognition; RT-PCR, reverse transcription PCR; Tdap, adult tetanus, diphtheria, and acellular pertussis vaccine; TMP/SMX, trimethoprim-sulfamethoxazole; Tx, treatment; —, not applicable.

immunologically naïve population. This policy will be focused on diagnosis, treatment, and prevention of the most common infections that may be encountered in the athlete participating in organized sports, with an additional focus on factors that are potentially modifiable. It should be noted that some of the organisms discussed can be transmitted in multiple fashions. Transmission of pathogens spread by contaminated food or water, by respiratory droplets, and by vectors are similar to what can be expected under nonsporting conditions⁵¹ and are beyond the scope of this report. Although several of these pathogens are summarized in Table 2, detailed descriptions in this clinical report are provided only for the organisms transmitted primarily by contact, manifesting primarily on the skin, and those that are airborne.

INFECTIONS PRIMARILY SPREAD BY CONTACT TRANSMISSION

Most sports-related skin infections are spread by contact and have been associated with 10% to 15% of time-loss injuries among athletes at the collegiate level.⁵² For this reason, routine screening of athletes participating in contact sports during practices and before competitions is important. The Sports Medicine Advisory Committee of the National Federation of State High School Associations (NFHS),⁵³ the National Collegiate Athletic Association (NCAA),⁵⁴ and the National Athletic Trainers Association (NATA)⁵⁵ have published guidelines for screening and when to return to athletic participation for several conditions (summarized in Table 3). It is noteworthy that many of the recommendations by these organizations are more stringent than ordinary infection control practices for similar conditions in which the likelihood of the type of close bodily contact is not as significant.

S Aureus

Community-acquired methicillin-resistant *S aureus* (MRSA) is a cause of outbreaks of skin infections among high school and collegiate athletes participating in contact sports, particularly among football players and wrestlers, and is associated with significant morbidity. It manifests primarily as cellulitis or skin abscesses but may lead to invasive disease such as bacteremia, septic arthritis, osteomyelitis, myositis, fasciitis, and pneumonia in up to 10% of cases.^{56,57} Other noninvasive forms of disease including impetigo, staphylococcal ecthyma, pustulosis, and folliculitis may also pose a risk for transmission of the organism from those so affected. Players who have preexisting skin diseases such as atopic dermatitis may have chronic colonization with *S aureus* and may be predisposed to recurrent secondary infection. Between 10% and 23% of football players or wrestlers have developed signs and symptoms during outbreaks.^{5,58–60} Risk factors for infection include skin breaks associated with turf burns or trauma,⁵⁸ skin-to-skin contact, sharing of equipment or clothing (towels), and higher BMI.^{5,19,59} Although 4% to 23% of athletes have been found to have colonization with MRSA, high colonization alone does not appear sufficient to trigger an outbreak.⁶¹ Wrestling mats, artificial turfs, and football training equipment have been documented with MRSA colonization.^{19,62,63}

Incidence estimates of MRSA-related skin and soft tissue infections in Nebraska student athletes have ranged from 11.3 to 20.9 per 10 000 football players and 28.1 to 60.8 per 10 000 wrestlers from 2008 to 2012.⁶⁴ Among 190 high school football players in northeast Ohio who were managed prospectively with nasal swab cultures, 23% displayed methicillin-susceptible *S aureus* colonization (none carried MRSA). Of the participating athletes,

10 (5.3%) developed skin infections, including 7 with impetigo and 1 with folliculitis barbae during the course of the 2008 season. None of the cultured specimens tested positive for MRSA.⁶⁵

Group A *Streptococcus*

Group A β -hemolytic *Streptococcus* (GABHS) has been associated with outbreaks of skin infections after indoor association football tournaments,⁶⁶ rugby,^{67,68} and other organized sports. The organism can cause localized skin infections such as pyoderma, cellulitis, or impetigo or invasive infections such as thrombophlebitis, myositis, and sepsis. GABHS has also been associated with outbreaks of pharyngitis among university students (median age 19.5 years) participating in judo.⁶⁹ Within a 15-day period, 12 of 23 club members in Tokyo, Japan, presented with sore throat and high fever. Diagnosis was made by use of either a rapid streptococcal antigen test or positive throat culture for GABHS when the clinical presentation was suggestive of pharyngitis. Occasionally, outbreaks of invasive GABHS disease have been reported in members of high school football teams,⁷⁰ likely attributable to sharing of equipment and water bottles.

Management of *S Aureus* and GABHS Outbreaks

Management of MRSA and GABHS outbreaks has been accomplished through meticulous focus on hygiene education, good hygiene practices, prompt identification of infected people, limiting exposure to infected people and contaminated surfaces and objects, decontamination of the environment, and proper treatment and close follow-up of infected people.^{4,5,7,59,60,69,71} Of particular importance for management of MRSA outbreaks is screening of players for carriage along with use of topical mupirocin for those found to have colonization, use of chlorhexidine

TABLE 3 Return to Practice and Competition Guidelines for Infected Athletes

Condition	NCAA ⁵⁴	NFHS ⁵³	NATA ⁵⁵	AAP Notes ⁵¹
GABHS and <i>S aureus</i> , (abscesses, cellulitis, folliculitis, impetigo, carbuncles)	<ul style="list-style-type: none"> • Completion of 72 h of antibiotic therapy • No new skin lesions for 48 h before competition • No moist, exudative, or draining lesions at time of practice or competition • Gram-stain of exudate of questionable lesions • Cannot cover active purulent lesions 	<ul style="list-style-type: none"> • Completion of 72 h of antibiotic therapy with lesions resolving • No moist, weeping, or draining lesions; all lesions should have well-adhering scabs • Scabbed and/or dry lesions only can be covered with bio-occlusive dressing 	<ul style="list-style-type: none"> • Completion of 72 h of antibiotic therapy with lesions resolving • No new skin lesions for at least 48 h • No moist, exudative, or draining lesions • Covered active lesions at time of practice or competition not allowed 	—
HSV, primary	<ul style="list-style-type: none"> • All systemic (fever, malaise, etc) symptoms must be resolved • No new lesions for 72 h before examination • No moist lesions, all existing lesions must be dry and covered by a firm, adherent crust • Must have been on appropriate systemic antiviral therapy for at least 5 d before and at the time of practice or competition • Covered active lesions at time of practice or competition not allowed 	<ul style="list-style-type: none"> • Return after all lesions are healed with well-adherent scabs, no new vesicles, no swollen lymph nodes near affected area • Oral antiviral agents to expedite recovery; if started, no wrestling for 5 d 	<ul style="list-style-type: none"> • All systemic (fever, malaise, etc) symptoms must be resolved • No new lesions for 72 h before examination • No moist lesions, all existing lesions must be dry and covered by a firm, adherent crust • Must have been on appropriate systemic antiviral therapy for at least 5 d before and at the time of competition • Covered active lesions at time of competition not allowed 	<ul style="list-style-type: none"> • Exclude athletes from practice or competition until vesicular or ulcerative lesions on exposed body parts and around mouth or eyes are fully crusted²⁶
HSV, recurrent	<ul style="list-style-type: none"> • Lesions must be completely dry and covered by a firm, adherent crust • Must have been on appropriate systemic antiviral therapy for at least 5 d before and at the time of competition • Covered active lesions at time of practice or competition not allowed 	<ul style="list-style-type: none"> • Oral antiviral agents to expedite recovery; if started, no wrestling for 5 d • If no oral antiviral agents, return after all lesions healed with well-adherent scabs, no new vesicles in previous 48 h, no swollen lymph nodes near affected area • Consider prophylactic antiviral agents for rest of season 	<ul style="list-style-type: none"> • Lesions must be completely dry and covered by a firm, adherent crust • Must have been on appropriate systemic antiviral therapy for at least 5 d before and at the time of competition • Covered active lesions at time of practice or competition not allowed 	<ul style="list-style-type: none"> • Exclude athletes from practice or competition until vesicular or ulcerative lesions on exposed body parts and around mouth or eyes are fully crusted • Consider suppressive antiviral agents for rest of season²⁶
Molluscum contagiosum	<ul style="list-style-type: none"> • Curette or remove lesions before competition • May cover solitary or localized clustered lesions with gas permeable membrane and tape 	<ul style="list-style-type: none"> • No treatment or restrictions • Cover lesions prone to bleeding when abraded with a gas-permeable membrane and tape 	<ul style="list-style-type: none"> • Lesions must be curetted or removed • Localized lesions may be covered with a gas-permeable dressing followed by underwrap and stretch tape 	—

TABLE 3 Continued

Condition	NCAA ⁵⁴	NFHS ⁵³	NATA ⁵⁵	AAP Notes ⁵¹
<i>T capitis</i>	<ul style="list-style-type: none"> • Minimum of 2 wk of systemic antifungal therapy • Presence of extensive and active lesions (based on KOH prep or review of treatment regimen) will lead to disqualification • Presence of solitary or closely clustered, localized lesions that cannot be covered will lead to disqualification 	<ul style="list-style-type: none"> • Minimum of 2 wk of systemic antifungal therapy 	<ul style="list-style-type: none"> • Minimum of 2 wk of systemic antifungal therapy 	—
<i>T corporis</i>	<ul style="list-style-type: none"> • Minimum of 72 h of topical or systemic antifungal therapy • Presence of extensive and active lesions (based on KOH prep or review of treatment regimen) will lead to disqualification • Presence of solitary or closely clustered, localized lesions that cannot be covered will lead to disqualification • Return to practice or competition decision made on an individual basis by examining physician and/or certified athletic trainer 	<ul style="list-style-type: none"> • Minimum of 72 h of topical or systemic antifungal therapy • Lesions to be covered with a bio-occlusive dressing for return to practice or competition once no longer considered contagious 	<ul style="list-style-type: none"> • Minimum 72 h topical fungicide terbinafine or naftifine • Lesions must be covered with a gas-permeable dressing followed by underwrap and stretch tape 	—
<i>T pedis</i>	—	—	—	Exclude from swimming pools, discourage from walking barefoot on locker room and shower floors until treatment has been initiated ^{28,37}
<i>T cruris</i>	—	—	—	Exclude from swimming pools until treatment has been initiated ^{28,37}
Verruca vulgaris (caused by subtypes of HPV)	<ul style="list-style-type: none"> • If multiple digitate lesions present on face, will be disqualified if cannot be covered by a mask • Solitary or scattered lesions should be curetted away before competition • Multiple verrucae plana or verrucae vulgaris must be “adequately covered” 	<ul style="list-style-type: none"> • No treatment or restrictions • Cover lesions prone to bleeding when abraded with a gas-permeable membrane and tape 	—	—
<i>S scabiei</i> (scabies) ³⁵	<ul style="list-style-type: none"> • Evidence of a negative microscopic skin prep before return to practice or competition 	—	—	—
<i>P capitis</i> ³⁶ (head lice)	<ul style="list-style-type: none"> • Appropriate pharmacologic treatment and reexamination for completeness of response before return 	—	—	—

TABLE 3 Continued

Condition	NCAA ⁵⁴	NFHS ⁵³	NATA ⁵⁵	AAP Notes ⁵¹
<i>Shigella</i>	—	—	—	<ul style="list-style-type: none"> Exclude until at least 24 h after diarrhea has ceased⁴⁵
<i>Giardia</i>	—	—	—	—
<i>Cryptosporidia</i>	—	—	—	<ul style="list-style-type: none"> Exclude from swimming while ill for 2 wk after illness completely resolved⁴⁷
Norovirus	—	—	—	<ul style="list-style-type: none"> Exclude from activities until 48 h after symptoms have resolved⁴⁸
Leptospirosis	—	—	—	<ul style="list-style-type: none"> Usually acquired from exposure to contaminated urine or body fluids of wild and domestic animals; no restrictions from contact sports because person-to-person spread is rare unless contact with wet fomites contaminated with human urine or rarely blood Risk is exposure to swimming, rafting, kayaking^a Early treatment with 5 d of a neuraminidase inhibitor (oseltamivir and zanamivir) recommended (decrease in duration of clinical symptoms would be warranted to reduce spread)⁴² Return when no longer febrile, respiratory symptoms resolved, and if on neuraminidase inhibitor; has completed 5 d of therapy
Influenza	—	—	—	<ul style="list-style-type: none"> Exclude from close contact until 5 d after initiation of effective therapy or until 3 wk after onset of cough⁴³
Pertussis	—	—	—	<ul style="list-style-type: none"> Exclude for at least 24 h after initiation of effective antimicrobial therapy⁴⁴
<i>N meningitidis</i>	—	—	—	<ul style="list-style-type: none"> Exclude for at least 24 h after initiation of effective antimicrobial therapy⁴⁴
V zoster	<ul style="list-style-type: none"> Skin lesions must have a firm, adherent crust at time of practice or competition There must be no evidence of secondary bacterial infection 	<ul style="list-style-type: none"> For shingles: 10–14 d of systemic antiviral medication Lesions must be scabbed over with no discharge and no new lesions in preceding 48 h 	—	<ul style="list-style-type: none"> Skin lesions must have a firm, adherent crust and no new lesions cropping up at time of practice or competition³⁹

AAP, American Academy of Pediatrics; KOH, potassium hydroxide; —, not applicable.

^a Centers for Disease Control and Prevention. Leptospirosis. Available at: <https://www.cdc.gov/leptospirosis/pdf/fact-sheet.pdf>. Accessed September 7, 2017.

washes, and enhancement of personal hygiene practices.^{7,19,72} Bleach baths (Clorox: regular 6.0% hypochlorite, 5 mL, added to 1 gallon of water) used twice weekly reduced the recurrence rates among children with community-associated *S aureus* infections by 20% compared with control children managed with routine hygienic measures, but this was not a statistically significant

reduction.⁷³ Screening for *S aureus* and GABHS requires knowledge of what body sites would have colonization. Nasal, skin, vaginal, and rectal carriage are the primary reservoirs for *S aureus*. In the context of sports-related infections, the primary culture sites should be the nares and any open skin lesions.

GABHS screening should be performed through vigorous

swabbing of a pair of swabs on both tonsils and the posterior pharynx for rapid antigen detection and culture as well as culture of any skin lesions, especially those that are oozing or macerated.²³ Measurement of sequential streptococcal antibody titers may also be used to diagnose a recent infection, but this is not recommended for routine use.⁷⁴

Skin abscesses are best managed by incision and drainage, with culture of the wound for identification of causative agent and antimicrobial susceptibility pattern along with empirical antibiotic coverage pending culture results. Antibiotic choices should be guided by knowledge of the local patterns of susceptibility of *S aureus*, especially local rates of MRSA. Methicillin-susceptible *S aureus* typically is treated with oral penicillinase-resistant β -lactam drugs, such as a first- or second-generation cephalosporin. For patients who are allergic to penicillin, or if MRSA is a significant consideration, the alternatives are trimethoprim-sulfamethoxazole, doxycycline, or clindamycin for susceptible isolates.²² Doxycycline can be used safely in children ages 2 years and older when given for durations less than 2 weeks. Trimethoprim-sulfamethoxazole should not be used as a single agent in the initial treatment of cellulitis because of the possibility it is caused by group A *Streptococcus* and the possibility of intrinsic resistance of this organism.^{75–77} Topical mupirocin may be used for localized and nonbullous impetigo. During outbreaks, attempts at eradication of *S aureus* infections to limit spread may be accomplished by use of topical nasal mupirocin therapy (twice daily for 5–7 days) among people with colonization. However, low-level (minimum inhibitory concentration, 8–256 $\mu\text{g}/\text{mL}$) and high-level (minimum inhibitory concentration, >512 $\mu\text{g}/\text{mL}$) resistance to mupirocin have been identified in *S aureus*. High-level resistance has been associated with subsequent failure of decolonization.

GABHS typically is susceptible to penicillin, and this is the usual first-line therapy.⁷⁴ An oral macrolide or azalide (eg, erythromycin, clarithromycin, or azithromycin) is acceptable for patients who are allergic to penicillin. Duration

of treatment is 10 days, with the exception of azithromycin, which is indicated for 5 days. Local mupirocin^{78–80} or retapamulin^{81–83} ointment may be useful for limiting person-to-person spread of nonbullous impetigo and for eradicating localized GABHS disease. Guidelines from the NCAA, NFHS, and NATA for when the infected athlete can return to competition for both GABHS and *S aureus* are summarized in Table 3.

Prevention of *S Aureus* and GABHS Outbreaks

Prevention of infections caused by MRSA and GABHS is achieved primarily through good hygiene practices, not sharing equipment and water bottles, limiting exposure to infected people and contaminated surfaces and objects, decontamination of the environment, and prompt identification, proper treatment, and close follow-up of infected people.^{4,5,7,59,60,69,71} Athletes with GABHS pharyngitis or skin infections should not return to competitive sports for at least 24 hours after beginning appropriate oral antimicrobial therapy.²³ Table 3 summarizes recommendations of the NCAA, NFHS, and NATA for return to competition for patients with *S aureus* infections, including MRSA.

Herpes Gladiatorum and Herpes Rubiginosum

HSV (primarily type 1) has been identified as a cause of outbreak of skin infections among wrestlers (herpes gladiatorum [HG]) and rugby players (herpes rubiginosum [HR]) on numerous occasions, affecting up to 2.6% of high school and 7.6% of college wrestlers in the United States.^{84–86} During outbreaks, up to 34% of all high school wrestlers have been documented to be infected.⁸⁷ Risk factors for development of HG-related cutaneous HSV lesions include direct skin-to-skin exposure to opponents with cutaneous lesions.⁸⁴ There is a range of 4 to

11 days, with an average of 6.80 ± 1.70 days from onset of exposure to development of skin lesions. Most outbreaks (96%) occur on the ventral surface of the body, with up to three-quarters of the cases occurring on areas in direct contact when wrestlers are engaged in the lock-up position (head, face, and neck). Other body areas frequently involved are the extremities (42%) and trunk (28%).¹⁶ HSV conjunctivitis (5%) and blepharitis have also been reported.⁸⁷ Between 25% and 40% of patients with HG and HR will develop constitutional symptoms including fever, chills, sore throat, and headaches.^{85,87} There are data associating acquired antibody to HSV type 1 infection with protection from acquiring HG, but the association is very weak.⁸⁴

Herpes Outbreak and High-Altitude Skiing

High-altitude skiing also has been associated with relapses of orofacial herpes, presumably because of solar UV radiation exposure, with a median onset of 3.5 days after exposure (strong evidence).⁸⁸ Although sunscreen with a sun protection factor of 15 was shown to prevent experimental UV light-induced reactivation of herpes labialis compared with placebo,⁸⁹ it has not been shown to influence the reactivation rate among high-altitude skiers.⁸⁸

Management of HG and HR Outbreaks

There is strong evidence that prompt identification and 3 to 8 days of isolation of infected wrestlers during primary outbreaks of HG and HR with suspension of competition can help contain outbreaks in more than 90% of cases.^{87,90,91} Diagnosis involves a combination of clinical recognition and may be coupled with cell culture, histologic examination, or rapid diagnostic tests such as direct fluorescent antibody staining, enzyme immunoassay, or polymerase chain

reaction (PCR) of vesicular lesion scrapings in complex, lingering, or unclear cases.²⁶ Valacyclovir, 500 mg, every day or twice a day for 7 days, when given within 24 hours of symptoms onset, has been shown to shorten the duration of time until HSV PCR clearance from lesions of adolescent and adult wrestlers with recurrent HG by 21% (from ~8.1 days with placebo to 6.4 days with valacyclovir).⁹² Wrestlers receiving valacyclovir should be advised about the importance of good hydration to minimize the risk of nephrotoxicity. Competitors often do not recognize or may deny possible infection. As a result, efforts to reduce transmission should include (1) examination of wrestlers and rugby players for vesicular or ulcerative lesions on exposed areas of their bodies and around their mouths or eyes before practice or competition by a person familiar with the appearance of mucocutaneous infections (including HSV, herpes zoster, and impetigo), (2) excluding athletes with these lesions from competition until all lesions are fully crusted or production of a physician's written statement indicating that their condition is noninfectious, and (3) cleaning of wrestling mats with a freshly prepared solution of household bleach (1 quarter cup of bleach in 1 gallon of water) applied for a minimum contact time of 15 seconds at least daily and preferably between matches.²⁶ NCAA, NFHS, and NATA guidelines for when the infected athlete can return to competition are summarized in Table 3.

Prevention of HG and HR Outbreaks

Athletes with a history of recurrent HG, HR, or herpes labialis should be considered for suppressive antiviral therapy. There is strong evidence that nucleoside analogues (valacyclovir) can suppress recurrent outbreaks of herpes. In a study involving 42 male wrestlers aged 13 to 31 years in Minnesota combining

double-blind randomization followed by an open enrollment onto treatment, participants with recurrent HG were treated during the first half of the season with either 500 mg of valacyclovir or placebo and in the second half with 1000 mg of valacyclovir. The 500 and 1000 mg doses of valacyclovir suppressed recurrence of outbreaks among 100% (7 out of 7 and 12 out of 12) of participants whose last recurrence was more than 2 years before. However, the doses were slightly less successful among those with recurrences within 2 years (11 out of 14 and 23 out of 25, respectively), with better results with the 1000 mg dosing.⁹³

Similarly, in a Minnesota study of 332 male wrestlers 13 to 20 years of age who participated at a 28-day wrestling camp, once-a-day prophylactic valacyclovir (1000 mg) starting 1 week before camp and continuing throughout camp reduced the incidence of clinical HG outbreaks by 87%. Among 55 of these wrestlers who were HSV type 1 immunoglobulin G seronegative at the beginning of the camp and had postcamp serologic testing performed, none developed detectable immunoglobulin M against HSV type 1 or HSV type 2.⁹⁴ However, there is need for a detailed risk–benefit analysis of using valacyclovir for prophylaxis in wrestlers who are seronegative for herpes.

Molluscum Contagiosum

Molluscum contagiosum is a common, benign viral skin infection presenting as skin-colored papules that develop a central umbilication as they age. Molluscum contagiosum affects 5% to 11% of children 0 to 16 years of age⁹⁵ and most commonly affects the trunk, face, and extremities. Molluscum contagiosum is mostly asymptomatic but may present with pain, itching, redness, or occasionally bacterial superinfection. Outbreaks of molluscum contagiosum

have most often been described in association with exposure to swimming in public pools and underlying eczema.^{3,95–97} Other factors associated with infection include young age (highest incidence in children younger than 14 years), living in close proximity, skin-to-skin contact, sharing of fomites, and residence in tropical climates.^{3,98}

Management of Molluscum Outbreaks

Resolution of uncomplicated molluscum contagiosum typically occurs spontaneously in 6 to 12 months, although complete resolution of lesions can take up to 4 years. Although no regimen has proven highly successful, 10% potassium hydroxide and cryotherapy with liquid nitrogen have been used to treat lesions that occur in locations that are cosmetically bothersome to patients or for patients with underlying skin conditions such as eczema. Both forms of treatment appear to have similar efficacy in children, but cryotherapy may be associated with postinflammatory hyperpigmentation or, uncommonly, scarring.^{99,100} Imiquimod was not shown to be of benefit compared with placebo in randomized controlled trials.^{101,102} Open-label and observational studies^{103,104} indicate that cantharidin can be an effective treatment of molluscum contagiosum; however, in 1 small randomized controlled trial of 29 patients, the improvement seen with cantharidin, although greater than with placebo, was not found to be statistically significant.¹⁰⁰ Guidelines from the NCAA, NFHS, and NATA for when the infected athlete can return to competition for molluscum are summarized in Table 3.

Prevention of Molluscum Contagiosum Outbreaks

Given the known associations of molluscum contagiosum, the best method of prevention would involve

avoiding of skin-to-skin contact with people known to have lesions (covering lesions), not sharing towels and other fomites, and limiting exposure to swimming pools that have recently been associated with known outbreaks.

Tinea Infections

T corporis and *T capitis* infections have been reported more frequently among high school wrestlers and judo practitioners (*T corporis gladiatorum* and *T capitis gladiatorum*) than among other athletes.^{8,105–112} Studies of the prevalence of *T corporis gladiatorum* have involved use of potassium hydroxide examination to aid diagnosis. In 1 such study, 24% of 29 wrestlers had lesions of *T corporis*, versus 0 in a control group of track team members ($P = .005$).¹⁰⁶ In another study, *T corporis* was detected in 10 of 19 boys (53%) 15 to 17 years of age belonging to a judo club in Kyoto, Japan.¹¹² The most common cause of *T capitis gladiatorum* is *Trichophyton tonsurans*, accounting for more than 80% of cases, but it may also be caused by *Trichophyton rubrum* and *Trichophyton mentagrophytes*.^{113,114} *T tonsurans* (primarily), *T mentagrophytes*, and *Microsporum canis* have also been isolated in high rates during outbreaks of *T capitis* (ringworm) among high school wrestlers in a wrestling boarding school in Turkey.^{109,115,116} These organisms have been isolated frequently from individual skin lesions and from wrestling mats.^{108,109}

Management of *T Corporis* and *T Capitis* Outbreaks

Both skin-based and oral medications are available for the treatment of *T corporis*, but *T capitis* is managed exclusively with oral medications, often with simultaneous application of topical treatment to the scalp (because of the need for hair follicle penetration). Skin-based

preparations for *T corporis* include but are not limited to azole creams (clotrimazole, econazole, ketoconazole, oxiconazole), allylamine creams and gels (1% gel of terbinafine and butenafine), and hydroxypyridone (ciclopirox) preparations. Although these all are reasonably effective, some preparations in some studies demonstrate superior cure rates. For example, terbinafine emulsion gel has a mycological cure rate superior to that of ketoconazole cream (94% versus 69%, respectively) with similar adverse events rates.¹¹⁷

Oral agents also have proven efficacious in the treatment of most cases of *T corporis*. Different doses and durations of itraconazole have been used in studies. Itraconazole, 100 mg, given orally once a day, was superior to griseofulvin, 500 mg, orally, once a day, when given for 15 days (87% mycological cure rate versus 57%, respectively, at the end of 2 weeks after completion of therapy) to adolescents and adults.¹¹⁸ In contrast, 200 mg of itraconazole was found to be superior to 250 mg of terbinafine when given for 7 days respectively in terms of clinical response rates when administered to adolescents and adults.¹¹⁹

For *T capitis*, the traditional treatment in children had been oral griseofulvin, 10 mg/kg per day, microsize formulation, given once daily for 6 to 8 weeks, although doses of griseofulvin as high as 20 to 25 mg/kg per day have been used.¹²⁰ Terbinafine, 125 or 250 mg (adjusted for age), given for 2 to 8 weeks, has recently been shown to have efficacy that is at least as good, with fewer adverse effects and fewer recurrences.^{116,121–123} Cochrane reviews have concluded that 4 weeks of terbinafine was equivalent to 8 weeks of griseofulvin.^{124,125} Similarly, oral fluconazole given for 4 weeks had similar efficacy to oral griseofulvin given for 6 weeks,^{126,127} although at least 1

study revealed the efficacy to be low for both regimens.¹²⁸ Itraconazole given for 2 weeks is also similar in efficacy to 6 weeks of griseofulvin, whereas terbinafine and itraconazole appear to have similar efficacy for treatment periods of 2 to 3 weeks.¹²⁴ However, terbinafine, itraconazole, and fluconazole are significantly more expensive than griseofulvin. Furthermore, griseofulvin appears to be superior for infections attributable to certain species of *Microsporum*, which may require 4 weeks' duration or more of therapy with terbinafine and itraconazole.^{122,129,130} Terbinafine appears superior for *T tonsurans*.¹²⁵

Prevention of *T Corporis* and *T Capitis* Outbreaks

Fluconazole, 100 mg per day for 3 days, given prophylactically before initiation of competitive interscholastic high school wrestling and given again 6 weeks into the season, has been reported to significantly reduce the incidence of *T corporis* from 67.4% to 3.5%.³⁰ However, the risk-benefit analysis of giving fluconazole prophylactically in this manner has not been determined, and its use should be in consultation with an infectious diseases expert.

T Pedis

T pedis (athlete's foot) presents as a fine scaly or vesiculopustular eruption that is often itchy. The lesions may involve all areas of the foot but commonly include the fissures and scaling between toes. Increased rates of *T pedis* have been well documented and common among swimmers and runners (especially marathon runners), with documented infections in up to 22%. The predominant causes are *T rubrum* and *T mentagrophytes*.¹³¹ Spread via direct contact with the organism, *T pedis* is prevalent in warm, humid environments and affects men more than women.¹³²

Obesity and diabetes are additional risk factors for *T pedis*.¹³³

Management of *T Pedis* Outbreaks

Numerous treatments (creams and oral medications) have been evaluated for treating *T pedis*. In randomized controlled trials in adults, ciclopirox olamine (a broad-spectrum hydroxypyridone antifungal with proven efficacy against *T rubrum*, *T mentagrophytes*, and *Epidermophyton floccosum*) cream or gel (0.77%) applied twice daily to the affected areas for 4 weeks has been shown to be effective in eradicating *T pedis* and superior to 1% clotrimazole cream or ciclopirox vehicle in achieving both clinical and mycological cure (~60% for ciclopirox olamine cream versus 6% for its vehicle only at end of treatment, and 85% versus 16% two weeks after treatment).^{134,135} There are no published studies of use of ciclopirox to treat *T pedis* in children, but a dosage of topical application twice a day is recommended for use in children older than 10 years.²⁸ Similarly, naftifine ointment applied twice daily for 4 weeks and sulconazole nitrate 1% cream applied daily for 4 to 6 weeks have been associated with significantly higher mycological clearance rates (57%–66%) compared with their vehicles alone (13%–34% cleared) and were associated with fewer relapses in treatment of *T rubrum*-related *T pedis*.^{136,137} However, sulconazole is not approved for use in children in the United States. More recently, topical azoles such as fenticonazole powder have been used in adults with up to 100% cure rates.¹³⁸ Terbinafine 1% cream applied daily for 1 week also has been used effectively to treat *T pedis*, with >93% mycological cure rate at 4 weeks, and is approved for children 12 years and older.¹³⁹ Luliconazole was recently reported as a 1% cream trial for *T pedis* in adults, but less than 50% of the participants were cured on this

regimen.¹⁴⁰ It is only approved by the US Food and Drug Administration for use in adults.

Terbinafine offers the advantage of once-daily dosing and can be given for briefer periods than skin-based treatments. Oral terbinafine, 250 mg, given once daily for 1 week, has similar efficacy (based on mycological cure rates at week 4) to 4 weeks of clotrimazole 1% cream applied twice a day but with faster clinical resolution.¹⁴¹ Oral terbinafine, 250 mg, also is similar in mycological efficacy to itraconazole, 100 mg, when given over a 2-week duration but may have a slightly lower rate of relapse. Terbinafine is well tolerated in children, with the most concerning potential adverse events being occasional isolated neutropenia and rare liver failure, typically in people with preexisting liver disease.

Prevention of *T Pedis* Outbreaks

The use of foot powder after bathing has been associated with a decline in the rates of *T pedis* in a random sampling of users of a swimming bath in Scotland from 8.5% to 2.1% over a 3.5-year period,¹⁴² mostly attributable to the decline in rates of *T mentagrophytes* from 5.3% to 0.5%. Experts believe that careful and thorough drying between the toes after showers, daily changes of socks, and periodic cleaning of athletic footwear can be helpful.

T Cruris

T cruris (jock itch or crotch rot) is a common pruritic fungal infection of the groin and adjacent skin.¹³³ Heat, humidity, and hyperhidrosis are predisposing factors, as is wearing of tight-fitting or wet clothing. Similar to *T pedis*, obesity and diabetes are additional risk factors for *T cruris*.¹³³

The predominant cause is *T rubrum* followed by *E floccosum* and *T mentagrophytes*.^{143,144} It may be spread by contaminated fomites (contaminated towels, hotel

bed sheets) or autoinoculation from hands or feet infected with *Tinea* from another body site (*Tinea unguium*, *T pedis*, or *Tinea manuum*).¹³³

Management of *T Cruris* Infection

Similar to *T pedis*, terbinafine 1% cream applied daily for 1 week has been used effectively to treat *T cruris* with a mycological cure rate of approximately 94% and is approved for children 12 years and older.¹¹⁷ Butenafine (a benzylamine derivative of clotrimazole) applied twice daily for 2 weeks and clotrimazole applied twice weekly for 4 weeks are also over-the-counter alternatives, but butenafine is only approved in adults.^{145–148} Oral itraconazole (100 mg daily for 2 weeks or 200 mg daily for 1 week) has been shown to be effective in adults for treating *T cruris* and superior to oral griseofulvin (500 mg daily for 2 weeks).^{118,149,150} Several other azole topical formulations (oxiconazole,¹⁵¹ luliconazole,¹⁵¹ sertaconazole,¹⁴⁴ eberconazole¹⁵²) have been shown to be effective in adults, but none have been studied in any detail in children.

Prevention of *T Cruris* Infection

Because of risk of spread from *T pedis*, covering active foot lesions with socks before wearing undershorts may reduce the likelihood of direct contamination. Furthermore, complete drying of the crural folds after bathing, and use of separate (clean) towels for drying the groin and other parts of the body may help reduce contamination.

Verruca Vulgaris

Verruca vulgaris (common skin warts) are benign epithelial proliferations of the skin and are caused by human papillomaviruses. They are typically painless, multiple in number, and occur on any epithelial surface, although most commonly on the hands, feet, and around and under the nails.³³ They

may be distinguished from calluses and corns by the presence of black dots (clotted blood vessels that have grown into the wart) when they are pared down as well as the associated loss of overlying dermatoglyphs. Although reports indicate that warts may occur in outbreaks among athletes, there are no published data on the prevalence. Reported risk factors appear to include sharing of equipment and exposure of unshod feet in common shower areas.³⁴ In a study of 146 adolescents who used locker rooms, 27% of those who used communal showers on a regular basis were found to have plantar warts versus only 1.25% of those who only used the locker rooms.³⁴ However, because the children using communal showers were also members of a swim club, it is unclear whether the communal shower or the swimming was the major contributing factor.

Management of Verruca Vulgaris Infections

Most cases of common warts will eventually spontaneously regress, with 30% regressing within 6 months and approximately 60% within 2 years. Treatment modalities are usually geared toward chemical or physical destruction of the infected epithelium and include techniques such as freezing with liquid nitrogen, application of salicylic acid-based products or tretinoin (retinoic acid) cream, surgical (paring) or laser removal, and use of topical immunomodulating agents.³⁴ The more destructive methods may lead to pain, which may inhibit athletic activity. More recently, cantharidin combined with podophyllotoxin-salicylic acid has been used in adults and reported to be effective but associated with pain and blistering.^{153,154}

Prevention of Verruca Vulgaris Infections

Precise mechanisms of preventing common warts are unknown. However, like most infections that

are transmitted by contact, avoidance of contact with people known to have common warts, not sharing equipment and towels, and wearing rubber soled flip-flops or sandals in communal showers may minimize risk.

Scabies and Lice

Scabies (caused by *Sarcoptes scabiei*) and lice (*P capitis*), although not commonly reported in sports, can be disqualifying if identified in children participating in organized, especially contact, sports. They are transmitted primarily through person-to-person contact. The scabies parasite can survive on clothing for up to 4 days without skin contact.³⁵ Lice do not survive away from the scalp more than 1 to 2 days without a blood meal, and although uncommon, can be transmitted by hair brushes, combs, hats, and hair ornaments.³⁷ The transmission, risk factors, recognition, diagnosis, treatment, and prevention are summarized in Table 2. Successful treatment of scabies can be achieved topically with permethrin 5% cream or oral ivermectin (not for pregnant women), but resistance has been reported to both.^{155,156} Pregnant women and infants may be treated with topical crotamiton or precipitated sulfur ointment. Head lice treatment requires attention not only to the live lice but also to eggs that may subsequently hatch. Treatment of head lice can be started with over-the-counter 1% permethrin lotion or with pyrethrin combined with piperonyl butoxide, both of which have good safety profiles.³⁶ Resistance to these over-the-counter agents is commonplace in many parts of the United States, and as such, alternative Food and Drug Administration–approved treatments may be necessary. For lice resistant to over-the-counter medications, treatment options include spinosad suspension, benzyl alcohol lotion, malathion,

or ivermectin lotion. Spinosad and ivermectin lotion are ovicidal, and a single treatment may be adequate, but no treatment is 100% ovicidal.^{155,156} Suffocant treatments, such as benzyl alcohol lotion or malathion lotion, require retreatment approximately 1 week later to kill any new lice that hatched from nits. For lice resistant to all topical agents, oral ivermectin in a single dose of 200 or 400 µg/kg may be used in infants weighing over 15 kg, with a second dose given after 9 to 10 days.³⁶

INFECTIONS PRIMARILY SPREAD BY AIRBORNE OR DROPLET ROUTE

Varicella-Zoster Virus

Although varicella has been reported as a cause of airborne sports-related infections,¹⁵⁷ such reports are rare in the era of immunization with the live attenuated vaccine against the virus. The varicella-zoster virus (VZV) manifests primarily as a generalized, pruritic, vesicular rash consisting of 250 to 500 lesions in different stages (crops) of development and crusting.³⁹ There is usually an associated low-grade fever, and there may be other systemic symptoms. Disease in vaccinated children is often milder and atypical in nature compared with the wild virus infection and requires a high index of suspicion. Diagnosis is usually made on the basis of a typical clinical picture coupled with history of exposure, but vesicular fluid or scab scraping can be used for confirmation by using PCR, direct fluorescent antibody assay, or VZV-specific culture. A significant increase in serum varicella immunoglobulin G antibody between acute and convalescent serum samples can also assist in diagnosis.

Management of VZV Infections

Isolation should be instituted for those suspected to have chickenpox until the diagnosis is either ruled out or all the lesions are crusted

over or in vaccinated children when there are no new lesions within a 24-hour period.³⁹ Oral acyclovir or valacyclovir given within 24 hours of rash onset results in only a modest decrease in symptoms and is not routinely recommended for most healthy children. It should be considered in otherwise healthy children who are at increased risk of moderate to severe varicella, including people older than 12 years, people with chronic cutaneous or pulmonary disorders, those receiving long-term salicylate therapy, and those on short, intermittent, or aerosolized courses of corticosteroids.³⁹

Prevention of VZV Infections

The most effective proven means of preventing VZV is via primary immunization with the live attenuated vaccine.³⁹ Children exposed to VZV should have their immunity evaluated, either through vaccination records or through serologic testing.

Measles

Measles is characterized by a prodrome of cough, coryza, and conjunctivitis with fever followed by maculopapular or morbilliform rash that begins on the face and spreads downward to the trunk and out to the extremities. Koplik spots, which are considered pathognomonic, also appear during the prodrome.⁴⁰ Patients are contagious 4 days before the rash to 4 days after the rash appears. Measles outbreaks have been reported during many different types of sporting events ranging from gymnastics to skiing and fencing,^{158–163} highlighting the importance of adequate vaccination of all athletes. Up to 5% of people who have received a single dose of vaccine at 12 months or older have vaccine failure. Among previously immunized people, primary vaccine failure (inadequate response to vaccine) is a more common cause of

failure than waning immunity. As a result, the current recommendations call for a 2-dose vaccine schedule for children and high-risk adults.⁴⁰

Mumps

Mumps is a systemic illness that presents with swelling of 1 or more of the salivary glands, typically the parotid glands. Up to one-third of mumps cases do not cause salivary gland swelling, presenting instead as a respiratory tract infection. Orchitis is a common complication after puberty, but it rarely leads to sterility. Approximately 10% of patients have an associated viral meningitis, and numerous other complications occur rarely, including permanent hearing loss, myocarditis, endocardial fibroelastosis, arthritis, thrombocytopenia, thyroiditis, mastitis, glomerulonephritis, pancreatitis, and oophoritis. The virus has been isolated from saliva from 7 days before through 8 days after onset of salivary gland swelling. Before introduction of mumps vaccine, outbreaks of mumps were common in the United States, primarily in crowded settings including schools, prisons, orphanages, and military facilities. Although the incidence of the disease has declined significantly with the introduction of the 2-dose schedule of the measles-mumps-rubella (MMR) vaccine, outbreaks still periodically occur, primarily because of incomplete vaccination.

Management of Measles and Mumps Outbreaks

Immunization is the cornerstone of managing measles and mumps outbreaks. All suspected cases of measles or mumps should be reported immediately, and every effort should be made for laboratory confirmation of the infection either through serologic testing or detection of virus from clinical specimens (throat washings, nasopharyngeal secretions, urine, and blood for measles and buccal swabs, throat

washings, saliva, or cerebrospinal fluid, if relevant, for mumps). In an outbreak setting, the MMR vaccine should be given to all people (>12 months) who lack evidence of immunity. For mumps, a second MMR dose should be offered to all students (including those in postsecondary school) who have received only 1 dose of MMR vaccine. A second MMR dose should also be considered for both conditions in children 1 to 4 years of age if they have only received 1 dose and there is an ongoing outbreak affecting preschool-aged children with community-wide transmission.⁴⁰

Prevention of Measles and Mumps Outbreaks

The most important method to prevent measles and mumps outbreaks is routine immunization of all children with a live attenuated vaccine, such as MMR or MMR-varicella vaccine, at age 12 through 15 months, with a second dose at 4 to 6 years of age, and people who are not documented to have been vaccinated during these periods.⁴⁰ People who have altered immunity (except HIV infection, unless they have severe immunosuppression) should not receive MMR vaccine. Furthermore, MMR-varicella vaccine should not be given to patients with HIV (even if these people have little to no immune compromise) because of a lack of safety data at the present time.

The epidemiology and outbreak control considerations for other conditions primarily transmitted via droplet and contaminated food and water are summarized in Table 2.

LEAD AUTHORS

H. Dele Davies, MD, MS, MHCM, FAAP
Mary Anne Jackson, MD, FAAP
Stephen G. Rice, MD, PhD, MPH, FAAP

COMMITTEE ON INFECTIOUS DISEASES, 2016–2017

Carrie L. Byington, MD, FAAP, Chairperson
Yvonne A. Maldonado, MD, FAAP, Vice Chairperson

Elizabeth D. Barnett MD, FAAP
James D. Campbell, MD, FAAP
H. Dele Davies, MD, MS, MHCM, FAAP
Ruth Lynfield, MD, FAAP
Flor M. Munoz, MD, FAAP
Dawn Nolt, MD, MPH, FAAP
Ann-Christine Nyquist, MD, MSPH, FAAP
Sean O'Leary, MD, MPH, FAAP
Mobeen H. Rathore, MD, FAAP
Mark H. Sawyer, MD, FAAP
William J. Steinbach, MD, FAAP
Tina Q. Tan, MD, FAAP
Theoklis E. Zaoutis, MD, MSCE, FAAP

EX OFFICIO

David W. Kimberlin, MD, FAAP – Red Book *Editor*
Michael T. Brady, MD, FAAP – Red Book *Associate Editor*
Mary Anne Jackson, MD, FAAP – Red Book *Associate Editor*
Sarah S. Long, MD, FAAP – Red Book *Associate Editor*
Henry H. Bernstein, DO, MHCM, FAAP – Red Book *Online Associate Editor*
H. Cody Meissner, MD, FAAP – Visual Red Book *Associate Editor*

LIAISONS

James Stevermer, MD – *American Academy of Family Physicians*
Amanda C. Cohn, MD, FAAP – *Centers for Disease Control and Prevention*
Karen M. Farizo, MD – *US Food and Drug Administration*

Marc Fischer, MD, FAAP – *Centers for Disease Control and Prevention*
Bruce G. Gellin, MD, MPH – *National Vaccine Program Office*
Richard L. Gorman, MD, FAAP – *National Institutes of Health*
Natasha Halasa, MD, MPH, FAAP – *Pediatric Infectious Diseases Society*
Joan L. Robinson, MD – *Canadian Paediatric Society*
Jamie Deseda-Tous, MD – *Sociedad Latinoamericana de Infectologia Pediatrica (SLIPE)*
Geoffrey R. Simon, MD, FAAP – *Committee on Practice Ambulatory Medicine*
Jeffrey R. Starke, MD, FAAP – *American Thoracic Society*

STAFF

Jennifer M. Frantz, MPH

COUNCIL ON SPORTS MEDICINE AND FITNESS EXECUTIVE COMMITTEE, 2016–2017

Cynthia R. LaBella, MD, FAAP, Chairperson
Margaret A. Brooks, MD, FAAP
Greg S. Canty, MD, FAAP
Alex Diamond, DO, FAAP
William Henrikus, MD, FAAP
Kelsey Logan, MD, FAAP
Kody A. Moffatt, MD, FAAP
Blaise Nemeth, MD, FAAP
Brooke Pengel, MD, FAAP
Andrew Peterson, MD, FAAP
Paul Stricker, MD, FAAP

LIAISONS

Mark Halstead, MD, FAAP – *American Medical Society for Sports Medicine*
Donald W. Bagnall – *National Athletic Trainers Association*

CONSULTANT

Neeru A. Jayanthi, MD

STAFF

Anjie Emanuel, MPH

ABBREVIATIONS

GABHS: group A β -hemolytic streptococcus
HG: herpes gladiatorum
HR: herpes rubrigorum
HSV: herpes simplex virus
MMR: measles-mumps-rubella
MRSA: methicillin-resistant *Staphylococcus aureus*
NATA: National Athletic Trainers Association
NCAA: National Collegiate Athletic Association
NFHS: National Federation of State High School Associations
PCR: polymerase chain reaction
VZV: varicella-zoster virus

DOI: <https://doi.org/10.1542/peds.2017-2477>

Address correspondence to H. Dele Davies, MD, MS, MHCM, FAAP. E-mail: dele.davies@unmc.edu

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2017 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

FUNDING: No external funding.

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

REFERENCES

1. Washington RL, Bernhardt DT, Gomez J, et al; Committee on Sports Medicine and Fitness and Committee on School Health. Organized sports for children and preadolescents. *Pediatrics*. 2001;107(6):1459–1462
2. Anish EJ. Viral hepatitis: sports-related risk. *Curr Sports Med Rep*. 2004;3(2):100–106
3. Braue A, Ross G, Varigos G, Kelly H. Epidemiology and impact of childhood molluscum contagiosum: a case series and critical review of the literature. *Pediatr Dermatol*. 2005;22(4):287–294
4. Centers for Disease Control and Prevention (CDC). Methicillin-resistant staphylococcus aureus infections among competitive sports participants—Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000–2003. *MMWR Morb Mortal Wkly Rep*. 2003;52(33):793–795
5. Centers for Disease Control and Prevention (CDC). Methicillin-resistant *Staphylococcus aureus* among players on a high school football team—New York City, 2007. *MMWR Morb Mortal Wkly Rep*. 2009;58(3):52–55
6. Choong KY, Roberts LJ. Molluscum contagiosum, swimming and bathing: a clinical analysis. *Australas J Dermatol*. 1999;40(2):89–92

7. Nguyen DM, Mascola L, Brancoft E. Recurring methicillin-resistant *Staphylococcus aureus* infections in a football team. *Emerg Infect Dis.* 2005;11(4):526–532
8. Poisson DM, Rousseau D, Defo D, Estève E. Outbreak of tinea corporis gladiatorum, a fungal skin infection due to *Trichophyton tonsurans*, in a French high level judo team. *Euro Surveill.* 2005;10(9):187–190
9. Redziniak DE, Diduch DR, Turman K, et al. Methicillin-resistant *Staphylococcus aureus* (MRSA) in the athlete. *Int J Sports Med.* 2009;30(8):557–562
10. Anderson BJ. Skin infections in Minnesota high school state tournament wrestlers: 1997-2006. *Clin J Sport Med.* 2007;17(6):478–480
11. Wilson EK, Deweber K, Berry JW, Wilckens JH. Cutaneous infections in wrestlers. *Sports Health.* 2013;5(5):423–437
12. Daly P, Gustafson R. Public health recommendations for athletes attending sporting events. *Clin J Sport Med.* 2011;21(1):67–70
13. Howe WB. Preventing infectious disease in sports. *Phys Sportsmed.* 2003;31(2):23–29
14. Tillett E, Loosemore M. Setting standards for the prevention and management of travellers' diarrhoea in elite athletes: an audit of one team during the Youth Commonwealth Games in India. *Br J Sports Med.* 2009;43(13):1045–1048
15. Centers for Disease Control and Prevention (CDC). Microbes in pool filter backwash as evidence of the need for improved swimmer hygiene - metro-Atlanta, Georgia, 2012. *MMWR Morb Mortal Wkly Rep.* 2013;62(19):385–388
16. Anderson BJ. The epidemiology and clinical analysis of several outbreaks of herpes gladiatorum. *Med Sci Sports Exerc.* 2003;35(11):1809–1814
17. Hostetter KS, Lux M, Shelley K, Drummond JL, Laguna P. MRSA as a health concern in athletic facilities. *J Environ Health.* 2011;74(1):18–25; quiz 42
18. Jessee KB, Middlemas DA, Mulder DK, Rehberg RS. Exposure of athletic trainers to potentially infectious bodily fluids in the high school setting. *J Athl Train.* 1997;32(4):320–322
19. Oller AR, Province L, Curless B. *Staphylococcus aureus* recovery from environmental and human locations in 2 collegiate athletic teams. *J Athl Train.* 2010;45(3):222–229
20. American College of Sports Medicine. *Health/Fitness Facility Standards and Guidelines.* 4th ed. Champaign, IL: Human Kinetics; 2012
21. American Academy of Pediatrics. Infections spread by blood and body fluids. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases.* 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015:158–161. (2018 edition in press)
22. American Academy of Pediatrics. Staphylococcal infections. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases.* Elk Grove Village, IL: American Academy of Pediatrics; 2015:715–732. (2018 edition in press)
23. American Academy of Pediatrics. Group A streptococcal infections. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases.* 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015:732–744. (2018 edition in press)
24. American Academy of Pediatrics. *Bacillus cereus* Infections. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases.* Elk Grove Village, IL: American Academy of Pediatrics; 2015:255–256. (2018 edition in press)
25. Centers for Disease Control and Prevention (CDC). Outbreak of cutaneous *Bacillus cereus* infections among cadets in a university military program—Georgia, August 2004. *MMWR Morb Mortal Wkly Rep.* 2005;54(48):1233–1235
26. American Academy of Pediatrics. Herpes simplex. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases.* Elk Grove Village, IL: American Academy of Pediatrics; 2015:432–445. (2018 edition in press)
27. American Academy of Pediatrics. Molluscum contagiosum. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases.* Elk Grove Village, IL: American Academy of Pediatrics; 2015:561–562. (2018 edition in press)
28. American Academy of Pediatrics. Tinea capitis. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases.* 30 ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015:778–783. (2018 edition in press)
29. American Academy of Pediatrics. Tinea corporis. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases.* Elk Grove Village, IL: American Academy of Pediatrics; 2015:781–783. (2018 edition in press)
30. Brickman K, Einstein E, Sinha S, Ryno J, Guinness M. Fluconazole as a prophylactic measure for tinea gladiatorum in high school wrestlers. *Clin J Sport Med.* 2009;19(5):412–414
31. American Academy of Pediatrics. Tinea pedis and tinea unguium. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases.* Elk Grove Village, IL: American Academy of Pediatrics; 2015:784–786. (2018 edition in press)
32. American Academy of Pediatrics. Tinea cruris. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases.* Elk Grove Village, IL: American Academy of Pediatrics; 2015:783–784. (2018 edition in press)
33. American Academy of Pediatrics. Human papillomaviruses. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases.* Elk Grove Village, IL: American Academy of Pediatrics; 2015:576–583. (2018 edition in press)
34. Johnson LW. Communal showers and the risk of plantar warts. *J Fam Pract.* 1995;40(2):136–138

35. American Academy of Pediatrics. Scabies. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases*. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015:702–704. (2018 edition in press)
36. American Academy of Pediatrics. Pediculosis capitis. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases*. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015:597–601. (2018 edition in press)
37. American Academy of Pediatrics. Infections spread by direct contact. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases*. Elk Grove Village, IL: American Academy of Pediatrics; 2015:156–157. (2018 edition in press)
38. American Academy of Pediatrics. Epstein-Barr virus infections. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases*. Elk Grove Village, IL: American Academy of Pediatrics; 2015:336–340. (2018 edition in press)
39. American Academy of Pediatrics. Varicella-zoster virus infections. In: Kimberlin D, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases*. Elk Grove Village, IL: American Academy of Pediatrics; 2015:846–860. (2018 edition in press)
40. American Academy of Pediatrics. Measles. In: Kimberlin D, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases*. Elk Grove Village, IL: American Academy of Pediatrics; 2015:535–547. (2018 edition in press)
41. American Academy of Pediatrics. Mumps. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases*. Elk Grove Village, IL: American Academy of Pediatrics; 2016:564–568. (2018 edition in press)
42. American Academy of Pediatrics. Influenza. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases*. Elk Grove Village, IL: American Academy of Pediatrics; 2015:476–493. (2018 edition in press)
43. American Academy of Pediatrics. Pertussis (whooping cough). In: Kimberlin D, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases*. Elk Grove Village, IL: American Academy of Pediatrics; 2015:608–621. (2018 edition in press)
44. American Academy of Pediatrics. Meningococcal infections. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases*. Elk Grove Village, IL: American Academy of Pediatrics; 2015:547–558. (2018 edition in press)
45. American Academy of Pediatrics. Shigella. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases*. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015:706–709. (2018 edition in press)
46. American Academy of Pediatrics. Giardia intestinalis (formerly Giardia lamblia and Giardia duodenalis) infections. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases*. Elk Grove Village, IL: American Academy of Pediatrics; 2015:353–355. (2018 edition in press)
47. American Academy of Pediatrics. Cryptosporidiosis. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases*. Elk Grove Village, IL: American Academy of Pediatrics; 2015:312–315. (2018 edition in press)
48. American Academy of Pediatrics. Norovirus and other human calicivirus infections. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases*. Elk Grove Village, IL: American Academy of Pediatrics; 2015:573–574. (2018 edition in press)
49. American Academy of Pediatrics. Leptospirosis. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. *Red Book: 2015 Report of the Committee on Infectious Diseases*. Elk Grove Village, IL: American Academy of Pediatrics; 2015:510–513. (2018 edition in press)
50. Brockmann S, Piechotowski I, Bock-Hensley O, et al. Outbreak of leptospirosis among triathlon participants in Germany, 2006. *BMC Infect Dis*. 2010;10:91
51. American Academy of Pediatrics. *Red Book: 2015 Report of the Committee on Infectious Diseases*. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015. (2018 edition in press)
52. Johnson R. Herpes gladiatorum and other skin diseases. *Clin Sports Med*. 2004;23(5):473–484, x
53. National Federation of State High School Association, Sports Medicine Advisory Committee. Sports related skin infections position statement and guidelines. 2014. Available at: <https://www.nfhs.org/sports-resource-content/sports-related-skin-infections-position-statement-and-guidelines/>. Accessed March 7, 2017
54. National Collegiate Athletic Association. *2014-15 NCAA Sports Medicine Handbook*. 25th ed. Indianapolis, IN: National Collegiate Athletic Association; 2014
55. Zinder SM, Basler RS, Foley J, Scarlata C, Vasily DB. National athletic trainers' association position statement: skin diseases. *J Athl Train*. 2010;45(4):411–428
56. Gouveia C, Gavino A, Bouchami O, et al. Community-associated methicillin-resistant *Staphylococcus aureus* lacking PVL, as a cause of severe invasive infection treated with linezolid. *Case Rep Pediatr*. 2013;2013:727824
57. Lu D, Holtom P. Community-acquired methicillin-resistant *Staphylococcus aureus*, a new player in sports medicine. *Curr Sports Med Rep*. 2005;4(5):265–270
58. Begier EM, Frenette K, Barrett NL, et al; Connecticut Bioterrorism Field Epidemiology Response Team. A high-morbidity outbreak of methicillin-resistant *Staphylococcus aureus* among players on a college football team, facilitated by cosmetic body

- shaving and turf burns. *Clin Infect Dis*. 2004;39(10):1446–1453
59. Hall AJ, Bixler D, Haddy LE. Multiclonal outbreak of methicillin-resistant *Staphylococcus aureus* infections on a collegiate football team. *Epidemiol Infect*. 2009;137(1):85–93
 60. Lindenmayer JM, Schoenfeld S, O’Grady R, Carney JK. Methicillin-resistant *Staphylococcus aureus* in a high school wrestling team and the surrounding community. *Arch Intern Med*. 1998;158(8):895–899
 61. Creech CB, Saye E, McKenna BD, et al. One-year surveillance of methicillin-resistant *Staphylococcus aureus* nasal colonization and skin and soft tissue infections in collegiate athletes. *Arch Pediatr Adolesc Med*. 2010;164(7):615–620
 62. Stanforth B, Krause A, Starkey C, Ryan TJ. Prevalence of community-associated methicillin-resistant *Staphylococcus aureus* in high school wrestling environments. *J Environ Health*. 2010;72(6):12–16
 63. Waninger KN, Rooney TP, Miller JE, Berberian J, Fujimoto A, Buttaro BA. Community-associated methicillin-resistant *Staphylococcus aureus* survival on artificial turf substrates. *Med Sci Sports Exerc*. 2011;43(5):779–784
 64. Buss BF, Connolly S. Surveillance of physician-diagnosed skin and soft tissue infections consistent with methicillin-resistant *Staphylococcus aureus* (MRSA) among Nebraska high school athletes, 2008-2012. *J Sch Nurs*. 2014;30(1):42–48
 65. Lear A, McCord G, Peiffer J, Watkins RR, Parikh A, Warrington S. Incidence of *Staphylococcus aureus* nasal colonization and soft tissue infection among high school football players. *J Am Board Fam Med*. 2011;24(4):429–435
 66. Falck G. Group A streptococcal skin infections after indoor association football tournament. *Lancet*. 1996;347(9004):840–841
 67. Ludlam H, Cookson B. Scrum kidney: epidemic pyoderma caused by a nephritogenic *Streptococcus pyogenes* in a rugby team. *Lancet*. 1986;2(8502):331–333
 68. Quoilin S, Lambion N, Mak R, et al. Soft tissue infections in Belgian rugby players due to *Streptococcus pyogenes* emm type 81. *Euro Surveill*. 2006;11(12):E061221.2
 69. Aoki A, Ashizawa T, Ebata A, Nasu Y, Fujii T. Group A *Streptococcus* pharyngitis outbreak among university students in a judo club. *J Infect Chemother*. 2014;20(3):190–193
 70. Manning SE, Lee E, Bambino M, et al. Invasive group A streptococcal infection in high school football players, New York City, 2003. *Emerg Infect Dis*. 2005;11(1):146–149
 71. Benjamin HJ, Nikore V, Takagishi J. Practical management: community-associated methicillin-resistant *Staphylococcus aureus* (CA-MRSA): the latest sports epidemic. *Clin J Sport Med*. 2007;17(5):393–397
 72. Archibald LK, Shapiro J, Pass A, Rand K, Southwick F. Methicillin-resistant *Staphylococcus aureus* infection in a college football team: risk factors outside the locker room and playing field. *Infect Control Hosp Epidemiol*. 2008;29(5):450–453
 73. Kaplan SL, Forbes A, Hammerman WA, et al. Randomized trial of “bleach baths” plus routine hygienic measures vs. routine hygienic measures alone for prevention of recurrent infections. *Clin Infect Dis*. 2014;58(5):679–682
 74. Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, Schwartz RH; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. *Clin Infect Dis*. 2002;35(2):113–125
 75. Hoskins TW, Bernstein LS. Trimethoprim/sulphadiazine compared with penicillin V in the treatment of streptococcal throat infections. *J Antimicrob Chemother*. 1981;8(6):495–496
 76. Kaplan EL, Johnson DR, Del Rosario MC, Horn DL. Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the United States between 1994 and 1997. *Pediatr Infect Dis J*. 1999;18(12):1069–1072
 77. Traub WH, Leonhard B. Comparative susceptibility of clinical group A, B, C, F, and G beta-hemolytic streptococcal isolates to 24 antimicrobial drugs. *Chemotherapy*. 1997;43(1):10–20
 78. Dagan R, Bar-David Y. Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant *Staphylococcus aureus* strains. *Antimicrob Agents Chemother*. 1992;36(2):287–290
 79. George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. *Br J Gen Pract*. 2003;53(491):480–487
 80. Goldfarb J, Crenshaw D, O’Horo J, Lemon E, Blumer JL. Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo. *Antimicrob Agents Chemother*. 1988;32(12):1780–1783
 81. Koning S, van der Wouden JC, Chosidow O, et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. *Br J Dermatol*. 2008;158(5):1077–1082
 82. Oranje AP, Chosidow O, Sacchidanand S, et al; TOC100224 Study Team. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. *Dermatology*. 2007;215(4):331–340
 83. Weinberg JM, Tyring SK. Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to *Staphylococcus aureus*. *J Drugs Dermatol*. 2010;9(10):1198–1204
 84. Becker TM, Kodsí R, Bailey P, Lee F, Levandowski R, Nahmias AJ. Grappling with herpes: herpes gladiatorum. *Am J Sports Med*. 1988;16(6):665–669
 85. Skinner GR, Davies J, Ahmad A, McLeish P, Buchan A. An outbreak of herpes rubiorum managed by vaccination of players and sociosexual contacts. *J Infect*. 1996;33(3):163–167
 86. Dworkin MS, Shoemaker PC, Spitters C, et al. Endemic spread of herpes simplex virus type 1 among adolescent wrestlers and their coaches. *Pediatr Infect Dis J*. 1999;18(12):1108–1109
 87. Belongia EA, Goodman JL, Holland EJ, et al. An outbreak of herpes gladiatorum

- at a high-school wrestling camp. *N Engl J Med.* 1991;325(13):906–910
88. Mills J, Hauer L, Gottlieb A, Dromgoole S, Spruance S. Recurrent herpes labialis in skiers. Clinical observations and effect of sunscreen. *Am J Sports Med.* 1987;15(1):76–78
 89. Rooney JF, Bryson Y, Mannix ML, et al. Prevention of ultraviolet-light-induced herpes labialis by sunscreen. *Lancet.* 1991;338(8780):1419–1422
 90. Anderson BJ. Managing herpes gladiatorum outbreaks in competitive wrestling: the 2007 Minnesota experience. *Curr Sports Med Rep.* 2008;7(6):323–327
 91. Stacey A, Atkins B. Infectious diseases in rugby players: incidence, treatment and prevention. *Sports Med.* 2000;29(3):211–220
 92. Anderson BJ. Valacyclovir to expedite the clearance of recurrent herpes gladiatorum. *Clin J Sport Med.* 2005;15(5):364–366
 93. Anderson BJ. The effectiveness of valacyclovir in preventing reactivation of herpes gladiatorum in wrestlers. *Clin J Sport Med.* 1999;9(2):86–90
 94. Anderson BJ. Prophylactic valacyclovir to prevent outbreaks of primary herpes gladiatorum at a 28-day wrestling camp. *Jpn J Infect Dis.* 2006;59(1):6–9
 95. Olsen JR, Gallacher J, Piguat V, Francis NA. Epidemiology of molluscum contagiosum in children: a systematic review. *Fam Pract.* 2014;31(2):130–136
 96. Castilla MT, Sanzo JM, Fuentes S. Molluscum contagiosum in children and its relationship to attendance at swimming-pools: an epidemiological study. *Dermatology.* 1995;191(2):165
 97. Niizeki K, Kano O, Kondo Y. An epidemic study of molluscum contagiosum. Relationship to swimming. *Dermatologica.* 1984;169(4):197–198
 98. Thompson AJ, Matinpour K, Hardin J, Hsu S. Molluscum gladiatorum. *Dermatol Online J.* 2014;20(6)
 99. Handjani F, Behazin E, Sadati MS. Comparison of 10% potassium hydroxide solution versus cryotherapy in the treatment of molluscum contagiosum: an open randomized clinical trial. *J Dermatolog Treat.* 2014;25(3):249–250
 100. Short KA, Fuller LC, Higgins EM. Double-blind, randomized, placebo-controlled trial of the use of topical 10% potassium hydroxide solution in the treatment of molluscum contagiosum. *Pediatr Dermatol.* 2006;23(3):279–281
 101. Coloe Dosal J, Stewart PW, Lin JA, Williams CS, Morrell DS. Cantharidin for the treatment of molluscum contagiosum: a prospective, double-blinded, placebo-controlled trial. *Pediatr Dermatol.* 2014;31(4):440–449
 102. Katz KA. Dermatologists, imiquimod, and treatment of molluscum contagiosum in children: righting wrongs. *JAMA Dermatol.* 2015;151(2):125–126
 103. Silverberg NB, Sidbury R, Mancini AJ. Childhood molluscum contagiosum: experience with cantharidin therapy in 300 patients. *J Am Acad Dermatol.* 2000;43(3):503–507
 104. Cathcart S, Coloe J, Morrell DS. Parental satisfaction, efficacy, and adverse events in 54 patients treated with cantharidin for molluscum contagiosum infection. *Clin Pediatr (Phila).* 2009;48(2):161–165
 105. Beller M, Gessner BD. An outbreak of tinea corporis gladiatorum on a high school wrestling team. *J Am Acad Dermatol.* 1994;31(2 pt 1):197–201
 106. Adams BB. Tinea corporis gladiatorum: a cross-sectional study. *J Am Acad Dermatol.* 2000;43(6):1039–1041
 107. el Fari M, Gräser Y, Presber W, Tietz HJ. An epidemic of tinea corporis caused by *Trichophyton tonsurans* among children (wrestlers) in Germany. *Mycoses.* 2000;43(5):191–196
 108. Hedayati MT, Afshar P, Shokohi T, Aghili R. A study on tinea gladiatorum in young wrestlers and dermatophyte contamination of wrestling mats from Sari, Iran. *Br J Sports Med.* 2007;41(5):332–334
 109. Ilkit M, Ali Saracli M, Kurdak H, et al. Clonal outbreak of *Trichophyton tonsurans* tinea capitis gladiatorum among wrestlers in Adana, Turkey. *Med Mycol.* 2010;48(3):480–485
 110. Kohl TD, Giesen DP, Moyer J Jr, Lisney M. Tinea gladiatorum: Pennsylvania's experience. *Clin J Sport Med.* 2002;12(3):165–171
 111. Stiller MJ, Klein WP, Dorman RI, Rosenthal S. Tinea corporis gladiatorum: an epidemic of *Trichophyton tonsurans* in student wrestlers. *J Am Acad Dermatol.* 1992;27(4):632–633
 112. Yonezawa M, Idei T, Takahashi K, Miyachi Y, Tanaka S, Mochizuki T. Outbreak of tinea corporis caused by infection with *Trichophyton tonsurans* in boys belonging to a judo club of a high school in Kyoto. *Skin Res.* 2004;3(2):220–226
 113. Adams BB. Tinea corporis gladiatorum. *J Am Acad Dermatol.* 2002;47(2):286–290
 114. Aghamirian MR, Ghiasian SA. A clinico-epidemiological study on tinea gladiatorum in Iranian wrestlers and mat contamination by dermatophytes. *Mycoses.* 2011;54(3):248–253
 115. Ergin S, Ergin C, Erdoğan BS, Kaleli I, Evliyaoğlu D. An experience from an outbreak of tinea capitis gladiatorum due to *Trichophyton tonsurans*. *Clin Exp Dermatol.* 2006;31(2):212–214
 116. Cáceres-Ríos H, Rueda M, Ballona R, Bustamante B. Comparison of terbinafine and griseofulvin in the treatment of tinea capitis. *J Am Acad Dermatol.* 2000;42(1 pt 1):80–84
 117. Bonifaz A, Saúl A. Comparative study between terbinafine 1% emulsion-gel versus ketoconazole 2% cream in tinea cruris and tinea corporis. *Eur J Dermatol.* 2000;10(2):107–109
 118. Bourlond A, Lachapelle JM, Aussems J, et al. Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea corporis and tinea cruris. *Int J Dermatol.* 1989;28(6):410–412
 119. Decroix J, Fritsch P, Picoto A, Thurlimann W, Degreiff H. Short-term itraconazole versus terbinafine in the treatment of superficial dermatomycosis of the glabrous skin (tinea corporis or cruris). *Eur J Dermatol.* 1997;7(5):353–357
 120. Gupta AK, Adam P, Dlova N, et al. Therapeutic options for the treatment of tinea capitis caused by *Trichophyton* species: griseofulvin versus the new oral antifungal agents, terbinafine,

- itraconazole, and fluconazole. *Pediatr Dermatol*. 2001;18(5):433–438
121. Friedlander SF, Aly R, Krafchik B, et al; Tinea Capitis Study Group. Terbinafine in the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel-group, duration-finding study. *Pediatrics*. 2002;109(4):602–607
 122. Fuller LC, Smith CH, Cerio R, et al. A randomized comparison of 4 weeks of terbinafine vs. 8 weeks of griseofulvin for the treatment of tinea capitis. *Br J Dermatol*. 2001;144(2):321–327
 123. Memisoglu HR, Erboz S, Akkaya S, et al. Comparative study of the efficacy and tolerability of 4 weeks of terbinafine therapy with 8 weeks of griseofulvin therapy in children with tinea capitis. *J Dermatolog Treat*. 1999;10(3):189–193
 124. Gonzalez U, Seaton T, Bergus G, Jacobson J, Martinez-Monzon C. Systemic antifungal therapy for tinea capitis in children. *Cochrane Database Syst Rev*. 2007;(4):CD004685
 125. Chen X, Jiang X, Yang M, et al. Systemic antifungal therapy for tinea capitis in children. *Cochrane Database Syst Rev*. 2016;(5):CD004685
 126. Dastghaib L, Azzizadeh M, Jafari P. Therapeutic options for the treatment of tinea capitis: griseofulvin versus fluconazole. *J Dermatolog Treat*. 2005;16(1):43–46
 127. Filho ST, Cucé LC, Foss NT, Marques SA, Santamaria JR. Efficacy, safety and tolerability of terbinafine for Tinea capitis in children: Brazilian multicentric study with daily oral tablets for 1,2 and 4 weeks. *J Eur Acad Dermatol Venereol*. 1998;11(2):141–146
 128. Foster KW, Friedlander SF, Panzer H, Ghannoum MA, Elewski BE. A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis. *J Am Acad Dermatol*. 2005;53(5):798–809
 129. Hamm H, Schwinn A, Bräutigam M, Weidinger G; The Study Group. Short duration treatment with terbinafine for tinea capitis caused by Trichophyton or Microsporum species. *Br J Dermatol*. 1999;140(3):480–482
 130. Tey HL, Tan ASL, Chan YC. Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis. *J Am Acad Dermatol*. 2011;64(4):663–670
 131. Auger P, Marquis G, Joly J, Attye A. Epidemiology of tinea pedis in marathon runners: prevalence of occult athlete's foot. *Mycoses*. 1993;36(1–2):35–41
 132. Kamihama T, Kimura T, Hosokawa JI, Ueji M, Takase T, Tagami K. Tinea pedis outbreak in swimming pools in Japan. *Public Health*. 1997;111(4):249–253
 133. Patel GA, Wiederkehr M, Schwartz RA. Tinea cruris in children. *Cutis*. 2009;84(3):133–137
 134. Evaluation of ciclopirox olamine cream for the treatment of tinea pedis: multicenter, double-blind comparative studies. *Clin Ther*. 1985;7(4):409–417
 135. Aly R, Fisher G, Katz I, et al. Ciclopirox gel in the treatment of patients with interdigital tinea pedis. *Int J Dermatol*. 2003;42(suppl 1):29–35
 136. Naftifine gel in the treatment of tinea pedis: two double-blind, multicenter studies. Naftifine Gel Study Group. *Cutis*. 1991;48(1):85–88
 137. Akers WA, Lane A, Lynfield Y, et al. Sulconazole nitrate 1% cream in the treatment of chronic moccasin-type tinea pedis caused by Trichophyton rubrum. *J Am Acad Dermatol*. 1989;21(4 pt 1):686–689
 138. Albanese G, Di Cintio R, Giorgetti P, Galbiati G, Ciampini M. Recurrent tinea pedis: a double blind study on the prophylactic use of fenticonazole powder. *Mycoses*. 1992;35(5–6):157–159
 139. Evans EG. A comparison of terbinafine (Lamisil) 1% cream given for one week with clotrimazole (Canesten) 1% cream given for four weeks, in the treatment of tinea pedis. *Br J Dermatol*. 1994;130(suppl 43):12–14
 140. Jarratt M, Jones T, Kempers S, et al. Luliconazole for the treatment of interdigital tinea pedis: a double-blind, vehicle-controlled study. *Cutis*. 2013;91(4):203–210
 141. Barnetson RS, Marley J, Bullen M, et al. Comparison of one week of oral terbinafine (250 mg/day) with four weeks of treatment with clotrimazole 1% cream in interdigital tinea pedis. *Br J Dermatol*. 1998;139(4):675–678
 142. Gentles JC, Evans EG, Jones GR. Control of tinea pedis in a swimming bath. *BMJ*. 1974;2(5919):577–580
 143. del Palacio Hernandez A, López Gómez S, González Lastra F, Moreno Palancar P, Iglesias Díez L. A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris. *Clin Exp Dermatol*. 1990;15(3):210–216
 144. Choudhary S, Bisati S, Singh A, Koley S. Efficacy and safety of terbinafine hydrochloride 1% cream vs. sertaconazole nitrate 2% cream in tinea corporis and tinea cruris: a comparative therapeutic trial. *Indian J Dermatol*. 2013;58(6):457–460
 145. Ramam M, Prasad HR, Manchanda Y, et al. Randomised controlled trial of topical butenafine in tinea cruris and tinea corporis. *Indian J Dermatol Venereol Leprol*. 2003;69(2):154–158
 146. Saple DG, Amar AK, Ravichandran G, Korde KM, Desai A. Efficacy and safety of butenafine in superficial dermatophytoses (tinea pedis, tinea cruris, tinea corporis). *J Indian Med Assoc*. 2001;99(5):274–275
 147. Singal A, Pandhi D, Agrawal S, Das S. Comparative efficacy of topical 1% butenafine and 1% clotrimazole in tinea cruris and tinea corporis: a randomized, double-blind trial. *J Dermatolog Treat*. 2005;16(5–6):331–335
 148. van Zuuren EJ, Fedorowicz Z, El-Gohary M. Evidence-based topical treatments for tinea cruris and tinea corporis: a summary of a Cochrane systematic review. *Br J Dermatol*. 2015;172(3):616–641
 149. Boonk W, de Geer D, de Kreek E, Remme J, van Huystee B. Itraconazole in the treatment of tinea corporis and tinea cruris: comparison of two treatment schedules. *Mycoses*. 1998;41(11–12):509–514
 150. Pariser DM, Pariser RJ, Ruoff G, Ray TL. Double-blind comparison of itraconazole and placebo in the treatment of tinea corporis and tinea cruris. *J Am Acad Dermatol*. 1994;31(2 pt 1):232–234
 151. Kalis B, Grosshans E, Binet O, et al. Oxiconazole cream versus ketoconazole cream. A prospective,

- randomized, double-blind, multicenter study in the treatment of inguinocrural dermatophytoses [in French]. *Ann Dermatol Venereol*. 1996;123(8):447–452
152. Choudhary SV, Aghi T, Bisati S. Efficacy and safety of terbinafine hydrochloride 1% cream vs eberconazole nitrate 1% cream in localised tinea corporis and tinea cruris. *Indian Dermatol Online J*. 2014;5(2):128–131
 153. Becerro de Bengoa Vallejo R, Losa Iglesias ME, Gómez-Martín B, Sánchez Gómez R, Sáez Crespo A. Application of cantharidin and podophyllotoxin for the treatment of plantar warts. *J Am Podiatr Med Assoc*. 2008;98(6):445–450
 154. López López D, Vilar Fernández JM, Losa Iglesias ME, et al. Safety and effectiveness of cantharidin-podophyllotoxin-salicylic acid in the treatment of recalcitrant plantar warts. *Dermatol Ther (Heidelb)*. 2016;29(4):269–273
 155. Koch E, Clark JM, Cohen B, et al. Management of head louse infestations in the United States—a literature review. *Pediatr Dermatol*. 2016;33(5):466–472
 156. Leulmi H, Diatta G, Sokhna C, Rolain JM, Raoult D. Assessment of oral ivermectin versus shampoo in the treatment of pediculosis (head lice infestation) in rural areas of Sine-Saloum, Senegal. *Int J Antimicrob Agents*. 2016;48(6):627–632
 157. Buescher ES. Infections associated with pediatric sport participation. *Pediatr Clin North Am*. 2002;49(4):743–751
 158. Centers for Disease Control and Prevention. From the Centers for Disease Control and Prevention. Interstate measles transmission from a ski resort—Colorado, 1994. *JAMA*. 1994;272(14):1097–1098
 159. Centers for Disease Control (CDC). Measles at an international gymnastics competition—Indiana, 1991. *MMWR Morb Mortal Wkly Rep*. 1992;41(7):109–111
 160. Centers for Disease Control and Prevention (CDC). Interstate measles transmission from a ski resort—Colorado, 1994. *MMWR Morb Mortal Wkly Rep*. 1994;43(34):627–629
 161. Centers for Disease Control and Prevention (CDC). Multistate measles outbreak associated with an international youth sporting event—Pennsylvania, Michigan, and Texas, August–September 2007. *MMWR Morb Mortal Wkly Rep*. 2008;57(7):169–173
 162. Ehresmann KR, Hedberg CW, Grimm MB, Norton CA, MacDonald KL, Osterholm MT. An outbreak of measles at an international sporting event with airborne transmission in a domed stadium. *J Infect Dis*. 1995;171(3):679–683
 163. Sasaki A, Suzuki H, Sakai T, Sato M, Shobugawa Y, Saito R. Measles outbreaks in high schools closely associated with sporting events in Niigata, Japan. *J Infect*. 2007;55(2):179–183